Table 3.
Interventional Clinical Trials Evaluating CAR-T Cell Platforms in Relapsed or Refractory Multiple Myeloma.
| Study NCT# | Reference URL | Study title | Phase of trial | CAR-T platform |
|---|---|---|---|---|
| NCT03287804 | https://ClinicalTrials.gov/show/NCT03287804 | A Single-Arm, Open-Label, Multi-Center, Phase 1/2 Study Evaluating the Safety and Clinical Activity of AUTO2, a CAR-T Cell Treatment Targeting BCMA and TACI in Patients With Relapsed or Refractory Multiple Myeloma | 1/2 | CAR-T BCMA + TACI |
| NCT03322735 | https://ClinicalTrials.gov/show/NCT03322735 | A Study of BCMA CAR-T Cells for Patients With Relapsed and Refractory Multiple Myeloma | 1/2 | CAR-T BCMA |
| NCT03661554 | https://ClinicalTrials.gov/show/NCT03661554 | BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma | 1 | CAR-T Nanobody/CAR-T BCMA |
| NCT03664661 | https://ClinicalTrials.gov/show/NCT03664661 | A Single-center, One Arm, Open-Label Clinical Study of BCMA Nanobody CAR-T Cells in Refractory/Relapsed Myeloma | 1 | CAR-T BCMA |
| NCT02546167 | https://ClinicalTrials.gov/show/NCT02546167 | Pilot Study of Redirected Autologous T Cells Engineered To Contain an Anti-BCMA scFv Coupled To TCRζ And 4-1BB Signaling Domains in Patients With Relapsed and/or Refractory Multiple Myeloma | 1 | CAR-T BCMA |
| NCT03548207 | https://ClinicalTrials.gov/show/NCT03548207 | A Phase 1b-2, Open-Label Study of JNJ-68284528, A Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Relapsed or Refractory Multiple Myeloma | 1/2 | JNJ-68284528/CAR-T BCMA |
| NCT03448978 | https://ClinicalTrials.gov/show/NCT03448978 | Phase 1 Safety and Feasibility Study of Autologous CD8+ T-cells Transiently Expressing a Chimeric Antigen Receptor Directed to B-Cell Maturation Antigen in Patients With Multiple Myeloma | 1 | CAR-T BCMA |
| NCT03318861 | https://ClinicalTrials.gov/show/NCT03318861 | A Phase 1 Multicenter Study of KITE-585, an Autologous Anti-BCMA CAR-T Cell Therapy, in Subjects With Relapsed/Refractory Multiple Myeloma | 1 | KITE-585/CAR-T BCMA |
| NCT03274219 | https://ClinicalTrials.gov/show/NCT03274219 | A Phase 1 Study of bb21217, an Anti-BCMA CAR- T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma | 1 | bb21217/CAR-T BCMA |
| NCT03361748 | https://ClinicalTrials.gov/show/NCT03361748 | A Phase 2, Multicenter Study to Determine the Efficacy and Safety of bb21217 in Subjects With Relapsed and Refractory Multiple Myeloma | 2 | bb21217/CAR-T BCMA |
| NCT03430011 | https://ClinicalTrials.gov/show/NCT03430011 | Protocol H125001: An Open-Label Phase 1/2 Study of JCARH125, BCMA-targeted Chimeric Antigen Receptor (CAR)-T Cells, in Subjects With Relapsed or Refractory Multiple Myeloma | 1/2 | JCARH125/CAR-T BCMA |
| NCT03288493 | https://ClinicalTrials.gov/show/NCT03288493 | Open-Label, Multicenter, Single Ascending Dose Study to Assess the Safety of P-BCMA-101 in Subjects With Relapsed and/or Refractory Multiple Myeloma (MM) | 1 | P-BCMA-101 CAR-T/CAR-T BCMA |
| NCT03196414 | https://ClinicalTrials.gov/show/NCT03196414 | Study of T Cells Targeting CD138/BCMA (CAR-T CD138/BCMA) for Chemotherapy Refractory and Relapsed Multiple Myeloma | 1/2 | CAR-T CD138/BCMA |
| NCT03464916 | https://ClinicalTrials.gov/show/NCT03464916 | A Phase 1, Open-Label, Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of the Safety and Efficacy of CAR2 Anti-CD38 A2 CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma | 1 | CAR-T CD38 |